Despite the advances in diagnostic biomarkers, making a conclusive diagnosis of early onset of neurodegeneration is a major challenge to neurologists worldwide. Use of biomarkers not only increase the chance of definite diagnosis of the disease but help in the development of novel therapeutics in a specific population. According to recent clinical findings, neurofilament light protein is a promising biomarker of early onset of neuronal injury in various neurologic disorders such as Huntington’s disease, and Alzheimer's disease in Down syndrome. References Byrne LM, et al. Neurofilament light protein in blood as a potential biomarker of neurodegeneration in Huntington's disease: a retrospective cohort analysis. The Lancet Neurology.
2017 Aug 1;16(8):601-9. Rafii MS. Diagnostic biomarkers of Alzheimer's disease in Down syndrome. The Lancet Neurology. 2018 Aug 29.
